KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest Expenses (2019 - 2025)

Royalty Pharma's Interest Expenses history spans 7 years, with the latest figure at $94.2 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 43.2% year-over-year to $94.2 million; the TTM value through Dec 2025 reached $307.7 million, up 36.43%, while the annual FY2025 figure was $307.7 million, 36.43% up from the prior year.
  • Interest Expenses for Q4 2025 was $94.2 million at Royalty Pharma, up from $79.6 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $94.2 million in Q4 2025 and bottomed at $37.4 million in Q1 2021.
  • The 5-year median for Interest Expenses is $47.0 million (2021), against an average of $53.7 million.
  • The largest annual shift saw Interest Expenses plummeted 30.18% in 2021 before it surged 47.54% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $47.0 million in 2021, then fell by 0.04% to $47.0 million in 2022, then increased by 0.64% to $47.3 million in 2023, then skyrocketed by 39.16% to $65.8 million in 2024, then soared by 43.2% to $94.2 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Interest Expenses are $94.2 million (Q4 2025), $79.6 million (Q3 2025), and $68.7 million (Q2 2025).